SciFluor Life Sciences, LLC, a Boston, MA-based developer of a late-stage fluorination technology that improves drug properties such as metabolic stability, potency, bioavailability, and blood-brain barrier penetration, has raised $5m in first funding round from Allied Minds.
The company intends to use the funds to commercialize its technology, which is based on research conducted by Professor Tobias Ritter (scientific founder and CTO of SciFluor) and colleagues in Harvard University’s Department of Chemistry and Chemical Biology.
SciFluor Life Sciences has an exclusive, worldwide license from Harvard University to various late- or end-stage fluorination methods and to a portfolio of novel fluorinated compounds.
As stated by Don Ciappenelli, Ph.D., General Manager of SciFluor, initially, the company will focus on partnering with companies in the biopharmaceutical industry and will establish collaborative programs for the synthesis of new fluorinated compounds to initiate, advance or improve preclinical drug candidates.
FinSMEs
17/05/2011